Nipro Diagnostics on Monday announced that the U.S. Food and Drug Administration approved two of its self-monitoring blood glucose systems, which will soon be added to its portfolio of diabetes monitoring and management products.
Manufacturing of the proprietary new blood glucose sensor technology incorporated into the TRUE METRIX and the TRUE METRIX PRO required significant capital investment, which will substantially expand manufacturing capabilities at Nipro Diagnostics’ Fort Lauderdale facility, the company said. That is where research and development, engineering and test strip manufacturing take place for all of the TRUE branded blood glucose products. In Fort Lauderdale, Nipro employs 480 people, which is nearly two-thirds of its worldwide workforce.
“With this investment, Nipro Diagnostics is building on its more than 25-year heritage of manufacturing blood glucose test strips in the United States. As we invest further in the U.S., this expansion will help us meet an ever-growing demand for blood glucose test strips as the number of people with diabetes is expected to continue to increase,” said Scott Verner, CEO and president of Nipro, a developer, manufacturer and marketer of diabetes monitoring and management products. “The TRUE METRIX blood glucose monitoring platform reinforces our commitment to offer an innovative, affordable solution for diabetes patients to lead healthier lives.”
The monitoring systems will be available through retail, mail and distribution channels beginning in the fourth quarter under partner brands or under Nipro Diagnostics’ own TRUE brand, the company said.
Sign Up and Save
Get six months of free digital access to the Miami Herald